{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-016118","form_type":"8-K","ticker":null,"cik":"0001267813","company_name":"MARINUS PHARMACEUTICALS, INC.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.933906+00:00","generated_at":"2026-05-29T05:04:05.231116+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Marinus Pharma receives Nasdaq bid price and market value deficiency notices","bullets":["Nasdaq notified MRNS that bid price closed below $1.00 for 30 consecutive days.","Company has until June 4, 2025 to regain compliance for a minimum 10 consecutive days.","Also notified that market value of listed securities remained below $50 million for 30 days.","Company may consider options to regain compliance but no assurance of success.","Failure to comply may result in delisting; company could appeal or transfer to Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-016118","json":"https://secwatch.observer/filing/0001558370-24-016118.json","markdown":"https://secwatch.observer/filing/0001558370-24-016118.md","text":"https://secwatch.observer/filing/0001558370-24-016118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267813/000155837024016118/0001558370-24-016118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267813/000155837024016118/mrns-20241206x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:04:05.231116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"232d0c28f9a82d144355abd021c3ef1f85a91381","claim":"MARINUS PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"December 6, 2024, Marinus Pharmaceuticals, Inc. (the “Company”) received written notice (the “Bid Price Deficiency Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the previous 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Bid Price Deficiency Notice has no effect at this time on the li","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000155837024016118/0001558370-24-016118-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}